Support for the UN Sustainable Development Goals

Across our value chain CSL’s activities support the achievement of the United Nations Sustainable Development goals, in particular:

Sustainable Development Goal	CSL's position and contribution
	CSL develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. CSL holds more than 1,000 product registrations (including varying vial sizes) in 106 countries, supporting newborns through to the elderly. Our support for patient groups and their programs helps to raise awareness and diagnosis of rare and serious diseases, improve access to our life-saving therapies and protect public health. in CSL’s Annual Report in section 6 and 9.
	CSL strives to create an open and trusting work environment characterised by equal opportunity, as well as a diverse, inclusive, collaborative and values-based culture. We rely on our people’s unique perspectives, ideas, capabilities and experiences to deliver for our business, our patients and our shareholders. We believe diversity and inclusion are crucial to strong business growth and performance. More information available in CSL’s Annual Report in section 7.
	Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise, thereby ensuring our continued growth. We enter into collaborative partnerships to further the science and prospects for successful product development. These partnerships often result in shared knowledge, intellectual property or products. For example, in Australia, as at 31 March 2021, there were 41 active research and development collaboration and licensing agreements. More information available in CSL’s Annual Report in section 6.
	CSL’s new carbon emissions reductions targets will serve as a transparent roadmap to decarbonise global operations by cutting direct and indirect carbon emissions. By 2030, the company: Is targeting a reduction of 40% of absolute Scope 1 & 2 emissions against a baseline of the average annual emissions across FY19-21; and Intends to ensure suppliers who contribute 67% of Scope 3 emissions have set Scope 1 & 2 reduction targets, aligned with the Science-based targets initiative. At CSL, we recognise that responsible management and efficient use of natural resources is a key to our sustainable growth and our ability to enable efficient and reliable supply of our life-saving medicines. We believe this makes us a stronger, more resilient business better prepared to navigate the future. More information available in CSL’s Annual Report in section 8.